7. PDS Biotechnology Corporation (NASDAQ:PDSB)
Closing Share Price $0.7485
Daily Increase 6.00%
Market Cap $41.89 Million
PDS Biotechnology Corporation (NASDAQ: PDSB) develops targeted cancer immunotherapies. Its pipeline includes PDS0101, a candidate being investigated for HPV-associated cancers. The business belongs in the clinical-stage biotechnology category, where the strength of trial results and the ability to advance development are essential considerations.
The shares rose 6.00% to close at $0.7485. That combination produced a score of 8.02, placing the company seventh in the countdown. The reported market capitalization was approximately $41.89 million, giving it a small public-market footprint despite the potentially significant medical needs its research addresses.
The quote provider reported a trailing net loss of approximately $33.67 million and no trailing revenue figure. Investors researching cancer treatment stocks should distinguish the potential of an investigational therapy from an established commercial business. Clinical outcomes, development expenses, and future financing can all influence shareholder returns, even when the stock initially looks affordable.
